

Welcome to STN International! Enter x:x

LOGINID:sssptaul25txc

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'USPATFULL' AT 12:07:59 ON 28 MAY 2003
FILE 'USPATFULL' ENTERED AT 12:07:59 ON 28 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	14.58	21.70

=> file uspatfull

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	15.85	22.97

FILE 'USPATFULL' ENTERED AT 12:08:18 ON 28 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 27 May 2003 (20030527/PD)
FILE LAST UPDATED: 27 May 2003 (20030527/ED)
HIGHEST GRANTED PATENT NUMBER: US6571393
HIGHEST APPLICATION PUBLICATION NUMBER: US2003097700
CA INDEXING IS CURRENT THROUGH 27 May 2003 (20030527/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 27 May 2003 (20030527/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s ciglitazone and 5 mg

414 CIGLITAZONE

3340772 5

306382 MG

88222 5 MG

(5(W)MG)

L6 277 CIGLITAZONE AND 5 MG

```
=> s ciglitazone (1P) 5 mg
      414 CIGLITAZONE
      3340772 5
      306382 MG
      88222 5 MG
      (5(W)MG)
L7      26 CIGLITAZONE (1P) 5 MG
```

```
=> d l7 and pd<1999
'AND' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'
'PD<1999' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'
```

The following are valid formats:

The default display format is STD.

```
ABS ----- AB
ALL ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
            RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
            DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
            INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
            EXF, ARTU
ALLG ----- ALL plus PAGE.DRAW
BIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
            PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ----- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE". BROWSE must
               entered on the same line as DISPLAY, e.g., D BROWSE.
CAS ----- OS, CC, SX, ST, IT
CBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ----- ALL, delimited for post-processing
FP ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
            PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,
            NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
            CLMN, DRWN, AB
FP.EX ----- FP for original and latest publication
FPALL ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
              RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,
              NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,
              PARN, SUMM, DRWD, DETD, CLM
FPBIB ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
              RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ----- HIT RN, its text modification, its CA index name, and
                its structure diagram
FPG ----- FP plus PAGE.DRAW
GI ----- PN and page image numbers
HIT ----- All fields containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
                its structure diagram
IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IALLG ----- IALL plus PAGE.DRAW
IBIB ----- BIB, indented with text labels
IBIB.EX ----- IBIB for original and latest publication
IBIBG ----- IBIB plus PAGE.DRAW
IMAX ----- MAX, indented with text labels
IMAX.EX ----- IMAX for original and latest publication
IND ----- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
            EXF, ARTU, OS, CC, SX, ST, IT
ISTD ----- STD, indented with text labels
```

KWIC ----- All hit terms plus 20 words on either side
 MAX ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
 RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
 DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
 INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
 EXF, ARTU OS, CC, SX, ST, IT
 MAX.EX ----- MAX for original and latest publication
 OCC ----- List of display fields containing hit terms
 SBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
 DT, FS, LN.CNT
 SCAN ----- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display
 without answer number. SCAN must be entered on the
 same line as DISPLAY, e.g., D SCAN)
 STD ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
 DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
 IC, ICM, ICS, EXF (STD is the default)
 STD.EX ----- STD for original and latest publication
 TRIAL ----- AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
 ICM, ICS

ENTER DISPLAY FORMAT (STD):STD

L7 ANSWER 1 OF 26 USPATFULL
 AN 2003:123367 USPATFULL
 TI Method of treating metabolic disorders especially diabetes, or a disease
 or condition associated with diabetes
 IN Gatlin, Marjorie Regan, Hoboken, NJ, United States
 Ball, Michele Ann, Morris Plains, NJ, United States
 Mannion, Richard Owen, Mount Arlington, NJ, United States
 Karnachi, Anees Abdulquadar, Hillsborough, NJ, United States
 Guitard, Christiane, Hegenheim, FRANCE
 Allison, Malcolm, Basel, SWITZERLAND
 PA Novartis AG, Basel, SWITZERLAND (non-U.S. corporation)
 PI US 6559188 B1 20030506
 AI US 2000-663264 20000915 (9)
 PRAI US 2000-304196P 20000407 (60)
 US 2000-240918P 20000309 (60)
 US 1999-242911P 19990917 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2176
 INCL INCLM: 514/641.000
 INCLS: 514/023.000; 514/057.000; 514/866.000
 NCL NCLM: 514/641.000
 NCLS: 514/023.000; 514/057.000; 514/866.000
 IC [7]
 ICM: A61K031-13
 ICS: A61K031-70; A61K031-715
 EXF 514/641; 514/866; 514/23; 514/57
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 17 1-26 bib,kwic

L7 ANSWER 1 OF 26 USPATFULL
 AN 2003:123367 USPATFULL
 TI Method of treating metabolic disorders especially diabetes, or a disease
 or condition associated with diabetes
 IN Gatlin, Marjorie Regan, Hoboken, NJ, United States
 Ball, Michele Ann, Morris Plains, NJ, United States
 Mannion, Richard Owen, Mount Arlington, NJ, United States
 Karnachi, Anees Abdulquadar, Hillsborough, NJ, United States

Guitard, Christiane, Hegenheim, FRANCE
Allison, Malcolm, Basel, SWITZERLAND

PA Novartis AG, Basel, SWITZERLAND (non-U.S. corporation)
PI US 6559188 B1 20030506
AI US 2000-663264 20000915 (9)
PRAI US 2000-304196P 20000407 (60)
US 2000-240918P 20000309 (60)
US 1999-242911P 19990917 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Weddington, Kevin E.

LREP Thallemer, John D.

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 2176

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . daily. Repaglinide is administered in a dosage of preferably 0.01 to 8 mg per meal, more preferably about 0.2 to 5 mg per meal, and most preferably 0.5 mg to 4 mg per meal.

SUMM . . . dosage of englitazone or darglitazone is preferably in the range of about 0.05 to 50, more preferably about 0.05 to 5, mg/kg body weight of the patient per day, if the warm-blooded animal is a human. The dosage of AY-31637 is in. . . to 100, mg/kg body weight of the patient per day, if the warm-blooded animal is a human. The dosage of **ciglitazone** is in the range of about 0.25 to 200, more preferably about 0.5 to 50, mg/kg body weight of the. . .

L7 ANSWER 2 OF 26 USPATFULL

AN 2001:226662 USPATFULL

TI Hypoglycemic thiazolidinediones and intermediates

IN Clark, David A., East Lyme, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 6329408 B1 20011211

AI US 1995-458071 19950601 (8)

RLI Division of Ser. No. US 1993-162027, filed on 1 Dec 1993, now abandoned
Continuation of Ser. No. WO 1992-US5436, filed on 1 Jul 1992
Continuation of Ser. No. US 1991-733771, filed on 22 Jul 1991, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: McKane, Joseph K.; Assistant Examiner: D'Souza, Andrea

LREP Richardson, Peter C., Benson, Gregg C., Ronau, Robert T.

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 776

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2. 5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al.; Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 3 OF 26 USPATFULL

AN 2001:158319 USPATFULL

TI Treating cancers associated with overexpression of class I family of receptor tyrosine kinases

IN Dannenberg, Andrew J., 7 Gracie Sq., Apt. 14A, New York, NY, United

States 10028

Subbaramaiah, Kotha, 43-23 Colden St., Apt. 17K, Flushing, NY, United States 11355

PI US 6291496 B1 20010918
AI US 1999-472179 19991227 (9)
DT Utility
FS GRANTED

EXNAM Primary Examiner: Eyler, Yvonne; Assistant Examiner: Andres, J.

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 796

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD A patient with HER-2/neu positive breast cancer is treated with **ciglitazone** or troglitazone or pioglitazone or rosiglitazone for adjuvant therapy at an oral dose of **5 mg/kg** twice per day for five years after a mastectomy. Recurrence of breast cancer does not occur.

DETD When GW 7845 or the compound of structure (II) or (III) is given at an oral dose of **5 mg/kg** twice per day for five years after a mastectomy in place of the thiazolidinedione, recurrence of breast cancer does not.

DETD . . . mg intravenous HERCEPTIN.RTM., then 10 weekly doses of 125 mg each IV. The patient also received an oral dose of **5 mg/kg** **ciglitazone** or troglitazone or pioglitazone or rosiglitazone twice daily for one year or **5 mg/kg** of GW 7845 or compound of structure (II) or (III) twice daily for one year. Recurrence of breast cancer does.

DETD . . . a mastectomy is performed on a patient with HER-2/neu positive breast cancer. The patient is treated with oral doses of **5 mg/kg** of **ciglitazone** or troglitazone or pioglitazone or rosiglitazone twice daily or **5 mg/kg** of GW 7845 or compound of structure (II) or (III) twice daily. A reduced tumor burden is noted.

DETD After failure of prior chemotherapy regimens, the patient is treated with an oral dose of **5 mg/kg** of **ciglitazone** or troglitazone or pioglitazone or rosiglitazone twice daily or **5 mg/kg** of GW 7845 or compound of structure (II) or (III) twice daily and HERCEPTIN.RTM. at a loading dose of 250. . .

DETD . . . to the bowel wall; there is no evidence of extracolonic cancer. The patient is treated with an oral dose of **5 mg/kg** of **ciglitazone** or troglitazone or pioglitazone or rosiglitazone twice daily or **5 mg/kg** of GW 7845 or compound of the structure (II) or (III) twice daily, for five years. Recurrence of colon cancer: . .

DETD . . . non-small cell lung carcinoma metastasized to liver, where EGFR is determined to be overexpressed, is treated with oral doses of **5 mg/kg** of **ciglitazone** or troglitazone or pioglitazone or rosiglitazone twice daily or **5 mg/kg** of GW 7845 or compound of structure (II) or (III) twice daily. A reduced tumor burden is noted. After one. . .

DETD . . . 60 mg/m². A reduced tumor burden is noted. At the end of the 12 week period, treatment is started with **5 mg/kg** twice daily by oral administration of **ciglitazone** or troglitazone or pioglitazone or rosiglitazone or GW 7845 or compound of structure (II) or (E) for 12 weeks. A. . .

DETD . . . a dose of 175 mg/m² administration intravenously every three weeks in further combination regimen with oral doses twice daily of **5 mg/kg** of **ciglitazone** or troglitazone or pioglitazone or rosiglitazone or GW 7845 or compound of structure (I) or (III). A reduced tumor burden. . .

DETD A patient with EGFR positive breast cancer is treated with

ciglitazone or troglitazone or pioglitazone or rosiglitazone or GW 7845 or compound of structure (II) or (III) at an oral dose of **5 mg/kg** twice per daily for five years after a mastectomy. Recurrence of breast cancer dose not occur.

L7 ANSWER 4 OF 26 USPATFULL
AN 1998:69051 USPATFULL
TI Secondary amines as antidiabetic and antiobesity agents
IN Dow, Robert L., Waterford, CT, United States
Wright, Stephen W., Old Lyme, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5767133 19980616
WO 9429290 19941222
AI US 1995-569152 19951214 (8)
WO 1994-IB117 19940520
19951214 PCT 371 date
19951214 PCT 102(e) date
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Aulakh, Charandit S.
LREP Richardson, Peter C., Benson, Gregg C., Ronau, Robert T.
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2986

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . is collected via an ocular bleed prior to any treatment. The blood sample is immediately diluted 1:5 with saline containing 2. **5 mg/ml** sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals are then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs are. . .

L7 ANSWER 5 OF 26 USPATFULL
AN 1998:65249 USPATFULL
TI Hypoglycemic hydroxyurea derivatives
IN Goldstein, Steven Wayne, Mystic, CT, United States
McDermott, Ruth Elsbree, Salem, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5763467 19980609
AI US 1997-840179 19970411 (8)
RLI Division of Ser. No. US 1995-544010, filed on 10 Oct 1995, now patented, Pat. No. US 5646168 which is a division of Ser. No. US 1995-391308, filed on 17 Feb 1995, now patented, Pat. No. US 5463070 which is a continuation of Ser. No. US 1994-279322, filed on 22 Jul 1994, now abandoned which is a division of Ser. No. US 1993-983538, filed on 22 Feb 1993, now patented, Pat. No. US 5334604 which is a continuation of Ser. No. US 1990-572745, filed on 23 Aug 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Daus, Donald G.
LREP Richardson, Peter C., Benson, Gregg C., Jones, James T.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1122

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2. **5 mg/ml** sodium fluoride and 2% sodium heparin, and

held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 6 OF 26 USPATFULL
AN 97:59226 USPATFULL
TI Hypoglycemic hydroxyurea derivatives
IN Goldstein, Steven Wayne, 176 Bel-Aire Dr., Mystic, CT, United States 06355
McDermott, Ruth Elsbree, 38 Meadow La., Salem, CT, United States 06420
PI US 5646168 19970708
AI US 1995-544010 19951010 (8)
RLI Division of Ser. No. US 1995-391308, filed on 17 Feb 1995, now patented, Pat. No. US 5463070 which is a continuation of Ser. No. US 1994-279322, filed on 22 Jul 1994, now abandoned which is a division of Ser. No. US 1993-983538, filed on 22 Feb 1993, now patented, Pat. No. US 5334604 which is a continuation of Ser. No. US 1990-572745, filed on 23 Aug 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Daus, Donald G.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1076
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2.

5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 7 OF 26 USPATFULL
AN 96:29574 USPATFULL
TI Thiazolidinedione compounds
IN Regnier, Gilbert, Chatenay Malabry, France
Charton, Yves, Sceaux, France
Duhault, Jacques, Croissy Sur Seine, France
Espinal, Joseph, Levallois Perret, France
PA ADIR et Compagnie, Courbevoie, France (non-U.S. corporation)
PI US 5506245 19960409
AI US 1995-374970 19950119 (8)
RLI Continuation-in-part of Ser. No. US 1993-133898, filed on 12 Oct 1993, now abandoned
PRAI FR 1992-12123 19921012
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Hueschen, Gordon W.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD TABLE 1

Doses causing the same hypoglycaemic effect
in ob/ob mice
Dose mg/kg/day

Compounds	for 4 days	Hypoglycaemic activity
-----------	------------	------------------------

Ciglitazone	50-100	100
Example 1	.1 to req. 10	100
Example 3	25	100
Example 4	10	100
Example 6	10	100
Example 7	25	100
Example 14	10	100

DETD . . . treated each day, for 10 days, by the oral administration of the compounds of the invention at a dose of **5 mg** /kg/day suspended in a 20% Senegal gum solution. On the 11th day the animals are sacrificed and blood is collected in. . .

L7 ANSWER 8 OF 26 USPATFULL
 AN 96:21101 USPATFULL
 TI Oxazolidinedione hypoglycemic agents
 IN Dow, Robert L., Waterford, CT, United States
 Hulin, Bernard, Essex, CT, United States
 Clark, David A., East Lyme, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5498621 19960312
 AI US 1994-289612 19940812 (8)
 RLI Continuation of Ser. No. US 1992-855038, filed on 1 May 1992, now abandoned
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Daus, Donald G.
 LREP Richardson, Peter C., Benson, Gregg C., Ronau, Robert T.
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1103

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2. **5 mg/ml** sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 9 OF 26 USPATFULL
 AN 95:97154 USPATFULL
 TI Hypoglycemic hydroxyurea derivatives
 IN Goldstein, Steven W., Mystic, CT, United States
 McDermott, Ruth E., Salem, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5463070 19951031
 AI US 1995-391308 19950217 (8)
 RLI Continuation of Ser. No. US 1994-279322, filed on 22 Jul 1994, now abandoned which is a division of Ser. No. US 1993-983538, filed on 22 Feb 1993, now patented, Pat. No. US 5334604 which is a continuation of Ser. No. US 1990-572745, filed on 23 Aug 1990, now abandoned
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Daus, Donald G.
 LREP Richardson, Peter C., Benson, Gregg C., Jones, James T.
 CLMN Number of Claims: 5
 ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1076

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2.5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 10 OF 26 USPATFULL

AN 95:69300 USPATFULL

TI 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents

IN Hulin, Bernard, Essex, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 5438074 19950801

AI US 1993-163781 19931206 (8)

RLI Division of Ser. No. US 1992-980404, filed on 24 Nov 1992, now patented, Pat. No. US 5306726 which is a continuation-in-part of Ser. No. US 1990-537673, filed on 14 Jun 1990, now patented, Pat. No. US 5089514

DT Utility

FS Granted

EXNAM Primary Examiner: Chan, Nicky

LREP Richardson, Peter C., Benson, Gregg C., Ronau, Robert T.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1,8

DRWN No Drawings

LN.CNT 1706

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2.5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 11 OF 26 USPATFULL

AN 95:27328 USPATFULL

TI Thiazolidinedione hypoglycemic agents

IN Goldstein, Steven W., Mystic, CT, United States

Hulin, Bernard, Essex, CT, United States

PA Pfizer, Inc., New York, NY, United States (U.S. corporation)

PI US 5401761 19950328

AI US 1993-162075 19931209 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Gerstl, Robert

LREP Richardson, Peter C., Benson, Gregg C., Brokke, Mervin E.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 643

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2.5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm.

Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 12 OF 26 USPATFULL

AN 94:66495 USPATFULL

TI Hypoglycemic hydroxyurea derivatives

IN Goldstein, Steven W., Mystic, CT, United States

McDermott, Ruth E., Salem, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 5334604 19940802

AI US 1993-983538 19930222 (7)

WO 1991-US4352 19910626

19930222 PCT 371 date

19930222 PCT 102(e) date

RLI Continuation of Ser. No. US 1990-572745, filed on 23 Aug 1990, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Daus, Donald G.

LREP Richardson, Peter C., Benson, Gregg C., McFarlin, D. Stuart

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1045

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2. 5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 13 OF 26 USPATFULL

AN 94:62459 USPATFULL

TI Thiazolidinedione derivatives as hypoglycemic agents

IN Clark, David A., East Lyme, CT, United States

Goldstein, Steven W., Mystic, CT, United States

Hulin, Bernard, Essex, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 5330998 19940719

AI US 1990-566437 19900814 (7)

WO 1988-US745 19880308

19900814 PCT 371 date

19900814 PCT 102(e) date

DT Utility

FS Granted

EXNAM Primary Examiner: Gerstl, Robert

LREP Richardson, Peter C., Benson, Gregg C., Brokke, Mervin E.

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1144

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2. 5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 14 OF 26 USPATFULL

AN 94:35602 USPATFULL
TI 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
IN Hulin, Bernard, Essex, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5306726 19940426
AI US 1992-980404 19921124 (7)
RLI which is a continuation-in-part of Ser. No. US 1990-537673, filed on 14 Jun 1990, now patented, Pat. No. US 5089514
DT Utility
FS Granted
EXNAM Primary Examiner: Daus, Donald G.
LREP Richardson, Peter C., Benson, Gregg C., Ronau, Robert T.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2. 5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 15 OF 26 USPATFULL
AN 93:52600 USPATFULL
TI Thiazolidinedione hypoglycemic agents
IN Clark, David A., East Lyme, CT, United States
Goldstein, Steven W., Mystic, CT, United States
Holland, Gerald F., Old Lyme, CT, United States
Hulin, Bernard, Essex, CT, United States
Rizzi, James P., Waterford, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5223522 19930629
AI US 1992-857039 19920324 (7)
RLI Division of Ser. No. US 1991-679898, filed on 3 Apr 1991, now patented, Pat. No. US 5120754 which is a division of Ser. No. US 1990-566436, filed on 14 Aug 1990, now patented, Pat. No. US 5061717
DT Utility
FS Granted
EXNAM Primary Examiner: Rotman, Alan L.
LREP Richardson, Peter C., Benson, Gregg C., Brokke, Mervin E.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2. 5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 16 OF 26 USPATFULL
AN 92:57744 USPATFULL
TI Hypoglycemic thiazolidinedione derivatives
IN Clark, David A., Groton, CT, United States
Goldstein, Steven W., Groton, CT, United States

Hulin, Bernard, Groton, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5130379 19920714
AI US 1991-674833 19910326 (7)
RLI Division of Ser. No. US 1990-477261, filed on 8 Feb 1990, now patented,
Pat. No. US 5036079 which is a continuation-in-part of Ser. No. US
1989-438490, filed on 7 Dec 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Rotman, Alan L.
LREP Richardson, Peter C., Lumb, J. Trevor, Brokke, Mervin E.
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1362

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The
blood sample was immediately diluted 1:5 with saline containing 2.
5 mg/ml sodium fluoride and 2% sodium heparin, and
held on ice for metabolite analysis. Animals were then dosed daily for
five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of
ciglitazone; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm.
Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 17 OF 26 USPATFULL

AN 92:47080 USPATFULL

TI Thiazolidinedione hypoglycemic agents

IN Clark, David A., East Lyme, CT, United States

Goldstein, Steven W., Mystic, CT, United States

Holland, Gerald F., Old Lyme, CT, United States

Hulin, Bernard, Essex, CT, United States

Rizzi, James P., Waterford, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 5120754 19920609

AI US 1991-679898 19910403 (7)

RLI Division of Ser. No. US 1990-566436, filed on 14 Aug 1990, now patented,
Pat. No. US 5061717

DT Utility

FS Granted

EXNAM Primary Examiner: Rotman, Alan L.

LREP Richardson, Peter C., Lumb, J. Trevor, Brokke, Mervin E.

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1604

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The
blood sample was immediately diluted 1:5 with saline containing 2.
5 mg/ml sodium fluoride and 2% sodium heparin, and
held on ice for metabolite analysis. Animals were then dosed daily for
five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of
ciglitazone; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm.
Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 18 OF 26 USPATFULL

AN 92:12971 USPATFULL

TI 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid
derivatives and analogs as hypoglycemic agents

IN Hulin, Bernard, Groton, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 5089514 19920218

AI US 1990-537673 19900614 (7)

DT Utility
FS Granted
EXNAM Primary Examiner: Daus, Donald G.
LREP Richardson, Peter C., Lumb, J. Trevor, McFarlin, D. Stuart
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1169

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2.5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 19 OF 26 USPATFULL

AN 91:89062 USPATFULL

TI Thiazolidinedione hypoglycemic agents

IN Clark, David A., East Lyme, CT, United States

Goldstein, Steven W., Mystic, CT, United States

Holland, Gerald F., Old Lyme, CT, United States

Hulin, Bernard, Essex, CT, United States

Rizzi, James P., Waterford, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 5061717 19911029

AI US 1990-566436 19900814 (7)

WO 1988-US744 19880308

19900814 PCT 371 date

19900814 PCT 102(e) date

DT Utility

FS Granted

EXNAM Primary Examiner: Rotman, Alan L.

LREP Richardson, Peter C., Lumb, J. Trevor, Brokke, Mervin E.

CLMN Number of Claims: 13

ECL Exemplary Claim: 1,11

DRWN No Drawings

LN.CNT 1594

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2.5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 20 OF 26 USPATFULL

AN 91:62804 USPATFULL

TI Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents

IN Goldstein, Steven W., Mystic, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 5037842 19910806

AI US 1990-533615 19900605 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Daus, Donald G.

LREP Richardson, Peter C., Lumb, J. Trevor, McManus, James M.

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 586

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2.5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs. . .

L7 ANSWER 21 OF 26 USPATFULL

AN 91:60822 USPATFULL

TI Hypoglycemic thiazolidinedione derivatives

IN Clark, David A., East Lyme, CT, United States

Goldstein, Steven W., Mystic, CT, United States

Hulin, Bernard, Essex, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 5036079 19910730

AI US 1990-477261 19900208 (7)

RLI Continuation-in-part of Ser. No. US 1989-438490, filed on 7 Dec 1989, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Rotman, Alan L.

LREP Richardson: Peter C., Lumb, J. Trevor, Blackwood, Robert K.

CLMN Number of Claims: 24

ECL Exemplary Claim: 1,21

DRWN No Drawings

LN.CNT 1330

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2.5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of **ciglitazone**; U.S. Pat. No. 4,467,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were. . .

L7 ANSWER 22 OF 26 USPATFULL

AN 90:85644 USPATFULL

TI Oxazolidin-2-one derivatives as hypoglycemic agents

IN Clark, David A., East Lyme, CT, United States

Johnson, Michael R., Chapel Hill, NC, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 4968707 19901106

WO 8809661 19881215

AI US 1989-460848 19891115 (7)

WO 1987-US1356 19870610

19891115 PCT 371 date

19891115 PCT 102(e) date

DT Utility

FS Granted

EXNAM Primary Examiner: Daus, Donald G.

LREP Richardson, Peter C., Lumb, J. Trevor, Blackwood, Robert K.

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 913

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . was collected via an ocular bleed prior to any treatment. The blood sample was immediately diluted 1:5 with saline containing 2.5 mg/ml sodium fluoride and 2% sodium heparin, and

held on ice for metabolite analysis. Animals were then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg of **ciglitazone**; U.S. Pat. No. 4,461,902; Sohda et al., Chem. Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs were.

L7 ANSWER 23 OF 26 USPATFULL

AN 90:6005 USPATFULL

TI Novel naphthalenyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents

IN Lombardo, Louis J., South Plainfield, NJ, United States

Alessi, Thomas R., Monmouth Junction, NJ, United States

PA American Home Products Corporation, New York, NY, United States (U.S. corporation)

PI US 4895861 19900123

AI US 1989-341609 19890421 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Gerstl, Robert

LREP Patton, Walter

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 867

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . lower blood glucose levels in diabetic mice. For example, 4-[1-(5-bromo-2-naphthalenyl)ethyl]-3H-1,2,3,5-oxathiadiazole 2-oxide, the compound of Example 1, at a dose of 5 mg/kg/day give comparable results to **ciglitazone** at 100 mg/kg/day.

DETD . . . 20 -6 137-138 (dec.)

H H 2-SO.sub.2 CH.sub.2
20 -3 170-171

H H 2-OCH.sub.2
20 4 101-103

H H 2-CHCH 5 4 146-147 (dec.)

Ciglitazone 100 -33

L7 ANSWER 24 OF 26 USPATFULL

AN 88:52199 USPATFULL

TI N-(1H-tetrazol-5-yl-alkylphenyl)polyfluoroalkanamides

IN Kees, Kenneth L., West Chester, PA, United States

PA American Home Products Corporation, New York, NY, United States (U.S. corporation)

PI US 4764623 19880816

AI US 1987-62270 19870615 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Hollrah, Glennon H.; Assistant Examiner: Springer, D. B.

LREP Jackson, Richard K.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 701

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . to be administered to a mammal suffering from excessive blood levels of glucose and/or insulin in an amount from about 5 mg./kg. to about 300 mg./kg. body weight or more per day. An optimum dosing regimen to achieve the desired therapeutic response. . . problem of precipitating hypoglycemic shock. In addition, the compounds of Examples 1 and 3 are more effective than the standard **ciglitazone** in reducing blood glucose levels.

L7 ANSWER 25 OF 26 USPATFULL
 AN 88:24416 USPATFULL
 TI Hypoglycemic thiazolidinediones
 IN Eggler, James F., Stonington, CT, United States
 Holland, Gerald F., Old Lyme, CT, United States
 Johnson, Michael R., Gales Ferry, CT, United States
 Volkmann, Robert A., Ledyard, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 4738972 19880419
 AI US 1987-67899 19870626 (7)
 RLI Continuation-in-part of Ser. No. US 1986-10081, filed on 29 Dec 1986,
 now patented, Pat. No. US 4703052
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Gerstl, Robert
 LREP Richardson, Peter C., Frost, Albert E., Blackwood, Robert K.
 CLMN Number of Claims: 23
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1318
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 SUMM . . . was collected via an ocular bleed prior to any treatment. The
 blood sample was immediately diluted 1:5 with saline containing 2.
 5 mg/ml sodium fluoride and 2% sodium heparin, and
 held on ice for metabolite analysis. Animals were then dosed daily for
 five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of
ciglitazone; U.S. Pat. No. 4,467,902; Sohda et al., Chem.
 Pharm. Bull., vol. 32, pp. 4460-4465, 1984), or vehicle All drugs were.

L7 ANSWER 26 OF 26 USPATFULL
 AN 88:13313 USPATFULL
 TI Hypoglycemic thiazolidinediones
 IN Kees, Kenneth L., West Chester, PA, United States
 Cheeseman, Robert S., Swedeland, PA, United States
 PA American Home Products Corporation, New York, NY, United States (U.S.
 corporation)
 PI US 4728739 19880301
 AI US 1987-62268 19870615 (7)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Gerstl, Robert
 LREP Jackson, Richard K.
 CLMN Number of Claims: 4
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 181
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 DETD TABLE

Experi-	Dose	Glucose (mg/dl)	Insulin (.mu.ml)
ment Drug	(mg/kg)		
1 control --		154 .+-. 10	182 + 9
Ciglitazone			
75		89 .+-. 7*	57 .+-. 7*
Example 1 75		94 .+-. 7*	

			3*	45 .+-. 2*
2	control --	139 .+-. 8		167 .+-. 14
	Ciglitazone 5	127 .+-. 5		156 .+-. 12
	Example 1 5	105 .+-. 6*		63 .+-. 7*
3	control --	137 .+-. 7		168 .+-. 24
	Ciglitazone 5	101 .+-. 7*		170 .+-. 10
	20	97 .+-. 7*		116 .+-. 14*
	75	92 .+-. 4*		59 .+-. 3*
+-. 75	87 .+-. 3*		51 .+-. 5*
				31 .+-. 7*
4	control --	120 .+-. 7		229 .+-. 25
	Ciglitazone 20	76 .+-. 5*		183 .+-. 20
	Example 2 20	81 .+-. 7*		137 .+-. 16*

*Significantly different from control. . . .
 DETD to be administered to a mammal suffering from excessive blood
 levels of glucose and/or insulin in an amount from about 5
 mg/kg to about 300 mg/kg body weight or more per day. An optimum
 dosing regimen to achieve the desired therapeutic response. . . .